Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2011

01-10-2011 | Case Report

Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection

Authors: Akihiko Numata, Tetsu Akimoto, Masaki Toshima, Yoshitaka Iwazu, Naoko Otani, Takuya Miki, Taro Sugase, Osamu Saito, Yoshitomo Hamano, Fumi Takemoto, Yoshihiko Ueda, Shigeaki Muto, Eiji Kusano

Published in: Clinical and Experimental Nephrology | Issue 5/2011

Login to get access

Abstract

In ordinary settings, human immunodeficiency virus (HIV)-associated nephropathy should be considered when HIV infection is associated with heavy proteinuria. On the other hand, hepatitis B virus (HBV) may also play a role in the development of glomerular injury among patients with HIV infection, since HIV and HBV infections commonly occur together due to shared modes of transmission. We present here a case of nephrotic syndrome in an HIV-positive patient complicated with HBV infection. A renal biopsy revealed sparse granular deposits of immunoglobulin G in the subepithelial region, consistent with membranous nephropathy (MN) stage I. Moreover, immunostaining exhibited weak anti-hepatitis B core activity within glomeruli. These results led us to consider that HBV-associated MN might play a role in the development of nephrotic syndrome. Although anti-viral treatment for patients with HBV-associated MN has been suggested to be clinically effective, the use of two anti-HIV agents (tenofovir and emtricitabine), both of which have anti-HBV activities, was not effective for the patient’s nephrotic syndrome, despite obtaining a decrease in the serum HBV-DNA levels. A lack of prospective data suggests that many decisions on the treatment of glomerulopathies with HIV infections are potentially empirical. Obviously, further studies and accumulated clinical experience are required to better determine the pathogenesis and management of HBV-associated MN among patients with HIV infections.
Literature
1.
go back to reference Boix E, Rivera F, Gil CM, Perez-Contreras J, Olivares J. Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrol Dial Transplant. 2000;15:412–4.CrossRefPubMed Boix E, Rivera F, Gil CM, Perez-Contreras J, Olivares J. Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrol Dial Transplant. 2000;15:412–4.CrossRefPubMed
3.
go back to reference Guerra IL, Abraham AA, Kimmel PL, Sabnis SG, Antonovych TT. Nephrotic syndrome associated with chronic persistent hepatitis B in an HIV antibody positive patients. Am J Kidney Dis. 1987;5:385–8.CrossRef Guerra IL, Abraham AA, Kimmel PL, Sabnis SG, Antonovych TT. Nephrotic syndrome associated with chronic persistent hepatitis B in an HIV antibody positive patients. Am J Kidney Dis. 1987;5:385–8.CrossRef
4.
go back to reference Schectman JM, Kimmel PL. Remission of hepatitis B-associated membranous glomerulonephritis in human immunodeficiency virus infection. Am J Kidney Dis. 1991;17:716–8.CrossRefPubMed Schectman JM, Kimmel PL. Remission of hepatitis B-associated membranous glomerulonephritis in human immunodeficiency virus infection. Am J Kidney Dis. 1991;17:716–8.CrossRefPubMed
5.
go back to reference Akimoto T, Otake T, Tanaka A, Takahashi H, Higashizawa T, Inoue M, et al. Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases. Clin Exp Nephrol. 2011;15:289–93.CrossRefPubMed Akimoto T, Otake T, Tanaka A, Takahashi H, Higashizawa T, Inoue M, et al. Steroid treatment in patients with membranous nephropathy and hepatitis B virus surface antigenemia: a report of two cases. Clin Exp Nephrol. 2011;15:289–93.CrossRefPubMed
6.
go back to reference Schwartz MM. Membranous nephropathy. In: Jennete JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51. Schwartz MM. Membranous nephropathy. In: Jennete JC, Olson JL, Schwartz MM, Silvia FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51.
7.
go back to reference Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003;23:400–5.CrossRefPubMed Jefferson JA, Couser WG. Therapy of membranous nephropathy associated with malignancy and secondary causes. Semin Nephrol. 2003;23:400–5.CrossRefPubMed
8.
go back to reference Mattana J, Siegal FP, Schwarzwald E, Molho L, Sankaran RT, Gooneratne R, et al. AIDS-associated membranous nephropathy with advanced renal failure: response to prednisone. Am J Kidney Dis. 1997;30:116–9.CrossRefPubMed Mattana J, Siegal FP, Schwarzwald E, Molho L, Sankaran RT, Gooneratne R, et al. AIDS-associated membranous nephropathy with advanced renal failure: response to prednisone. Am J Kidney Dis. 1997;30:116–9.CrossRefPubMed
9.
10.
go back to reference Chuang TW, Hung CH, Huang SC, Lee CM. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007;106:869–73.CrossRefPubMed Chuang TW, Hung CH, Huang SC, Lee CM. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007;106:869–73.CrossRefPubMed
11.
go back to reference Koike K, Kikuchi Y, Kato M, Takamatsu J, Shintani Y, Tsutsumi T, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res. 2008;38:310–4.CrossRefPubMed Koike K, Kikuchi Y, Kato M, Takamatsu J, Shintani Y, Tsutsumi T, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res. 2008;38:310–4.CrossRefPubMed
12.
go back to reference Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169–77.CrossRefPubMed Lascar RM, Lopes AR, Gilson RJ, Dunn C, Johnstone R, Copas A, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169–77.CrossRefPubMed
13.
go back to reference Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999;180:1050–6.CrossRefPubMed Notermans DW, Pakker NG, Hamann D, Foudraine NA, Kauffmann RH, Meenhorst PL, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis. 1999;180:1050–6.CrossRefPubMed
14.
go back to reference Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185–92.CrossRefPubMed Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185–92.CrossRefPubMed
15.
go back to reference Gan SI, Devlin SM, Scott-Douglas NW, Burak KW. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection. Can J Gastroenterol. 2005;19:625–9.CrossRefPubMed Gan SI, Devlin SM, Scott-Douglas NW, Burak KW. Lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis B infection. Can J Gastroenterol. 2005;19:625–9.CrossRefPubMed
16.
go back to reference Okuse C, Yotsuyanagi H, Yamada H, Ikeda H, Takahashi H, Suzuki M, et al. Successful treatment of hepatitis B virus associated membranous nephropathy with lamivudine. Clin Nephrol. 2006;65:53–6.CrossRefPubMed Okuse C, Yotsuyanagi H, Yamada H, Ikeda H, Takahashi H, Suzuki M, et al. Successful treatment of hepatitis B virus associated membranous nephropathy with lamivudine. Clin Nephrol. 2006;65:53–6.CrossRefPubMed
17.
go back to reference Kannaan N, Horsmans Y, Goffin E. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol. 2006;65:208–10.CrossRef Kannaan N, Horsmans Y, Goffin E. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol. 2006;65:208–10.CrossRef
18.
go back to reference Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.CrossRefPubMedPubMedCentral Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.CrossRefPubMedPubMedCentral
19.
go back to reference Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMed Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMed
20.
go back to reference Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992;16:13–8.CrossRefPubMed Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992;16:13–8.CrossRefPubMed
21.
go back to reference Smith MC, Pawar R, Carey JT, Graham RC, Jacobs GH, Menon A, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med. 1994;97:145–51.CrossRefPubMed Smith MC, Pawar R, Carey JT, Graham RC, Jacobs GH, Menon A, et al. Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med. 1994;97:145–51.CrossRefPubMed
22.
go back to reference Herman ES, Klotman PE. HIV-associated nephropathy: epidemiology, pathogenesis, and treatment. Semin Nephrol. 2003;23:200–8.CrossRefPubMed Herman ES, Klotman PE. HIV-associated nephropathy: epidemiology, pathogenesis, and treatment. Semin Nephrol. 2003;23:200–8.CrossRefPubMed
23.
go back to reference Masuda T, Akimoto T, Ando Y, Kobayashi T, Meguro D, Muto S, et al. Changes in the urinary excretion of β2-microglobulin (β2MG) and N-acetyl-β-d-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med. 2008;47:287–90.CrossRefPubMed Masuda T, Akimoto T, Ando Y, Kobayashi T, Meguro D, Muto S, et al. Changes in the urinary excretion of β2-microglobulin (β2MG) and N-acetyl-β-d-glucosaminidase (NAG) during treatment for lupus nephritis. Intern Med. 2008;47:287–90.CrossRefPubMed
Metadata
Title
Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection
Authors
Akihiko Numata
Tetsu Akimoto
Masaki Toshima
Yoshitaka Iwazu
Naoko Otani
Takuya Miki
Taro Sugase
Osamu Saito
Yoshitomo Hamano
Fumi Takemoto
Yoshihiko Ueda
Shigeaki Muto
Eiji Kusano
Publication date
01-10-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0477-2

Other articles of this Issue 5/2011

Clinical and Experimental Nephrology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.